Real practice studies in oncology: A positive perspective.

Area of Science:

• Oncology
• Clinical Research Methodology

Background:

• Phase III clinical trials frequently exclude patients with comorbidities, specific performance statuses (ECOG ≥ 2), advanced age (≥ 65 years), prior malignancies, brain metastases, infections, psychiatric disorders, non-measurable disease, or extensive prior therapies.
• This rigorous patient selection raises questions about the applicability of clinical trial results to the broader, more heterogeneous patient population encountered in routine clinical practice.

Discussion:

• The terms "real world" and "real practice" are often perceived as separate from, and even contradictory to, traditional clinical trial protocols.
• There's a need to shift the perspective from viewing retrospective, real-world studies as inherently "wrong" compared to prospective, randomized trials.
• Rigorous analysis of biases within real-world data can enhance interpretation and potentially strengthen findings, even generating new hypotheses.

Key Insights:

• Clinical trials' strict exclusion criteria limit the generalizability of findings to the diverse patient population.
• Real-world evidence, despite potential biases, offers valuable insights when analyzed rigorously.
• A balanced integration of clinical trial data and real-world studies is essential for advancing knowledge on anti-cancer drug efficacy.

Outlook:

• Future research should focus on integrating real-world data analysis with clinical trial methodologies.
• Developing standardized approaches for analyzing and reporting real-world evidence will improve its utility.
• This synergistic approach will ultimately enhance the understanding and application of anti-cancer therapies in diverse patient populations.